РОЛЬ АДРОПИНА ПРИ НАРУШЕНИЯХ МЕТАБОЛИЗМА И КАРДИОВАСКУЛЯРНОЙ ПАТОЛОГИИ (ОБЗОР ЛИТЕРАТУРЫ)

Аннотация

Несмотря на значительные достижения медицины сердечно-сосудистые заболевания продолжают оставаться ведущей причиной смертности во всем мире. Очень актуальной задачей является поиск и изучение новых сердечно-сосудистых биологических маркеров, способных помогать ранней диагностике заболеваний сердца, служить инструментом оценки эффективности лечения, выступать в роли прогностического маркера и критерия стратификации риска. Представленный литературный обзор указывает на потенциально важную диагностическую и прогностическую значимость оценки адропина. Ожидается, что дальнейшие научные и клинические исследования продемонстрируют возможность его использования в качестве дополнительного лабораторного инструмента диагностики и оценки прогноза у пациентов кардиологического профиля. Регуляция концентрации и экспрессии адропина, возможно, окажется многообещающей стратегией для лечения патологии сердца и сосудов.

Annotation

Despite significant advances in medicine, cardiovascular diseases continue to be the leading cause of mortality worldwide. A very urgent task is the search and study of new cardiovascular biological markers that can help early diagnosis of heart disease, serve as a tool to assess the effectiveness of treatment, act as a prognostic marker and risk stratification criteria. The presented literature review indicates the potentially important diagnostic and prognostic significance of adropin assessment. It is expected that further scientific and clinical studies will demonstrate the possibility of its use as an additional laboratory tool for diagnosis and prognosis assessment in cardiac patients. Regulation of adropin concentration and expression may prove to be a promising strategy for the treatment of cardiovascular pathology.

Об авторах

Список литературы

1. World Health Organization. Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019. World Health Organization; Geneva, Switzerland: 2020.
2. Roger V.L. Epidemiology of Heart Failure: A Contemporary Perspective. Circ. Res. 2021; 128 (10): 1421-34. DOI: 10.1161/CIRCRESAHA.121.318172.
3. Aliyeva A.M., Reznik E.V., Hasanova E.T., Zhbanov I.V., Nikitin I.G. Clinical value of blood biomarkers in patients with chronic heart failure. Arkhiv vnutrenney meditsiny. 2018; 8(5):333-45. DOI: 10.20514/2226-6704-2018-8-5-333-345. (in Russian)
4. Alieva A.M., Pinchuk T.V., Voronkova K.V., Shnakhova L.M., Ettinger O.A., Akhmedova M.F. et al. Neopterin is a biomarker of chronic heart failure (review of modern literature). Consilium Medicum. 2021; 23 (10): 756-9. DOI: 10.26442/20751753.2021.10.201113. (in Russian)
5. Aliyevа A.M., Almazova I.I., Pinchuk T.V., Resnick E.V., Fedulaev Yu.N., Nikitin I.G. The value of copeptin in the diagnosis and prognosis of cardiovascular diseases. Klinicheskaya meditsina. 2020; 98 (3): 203-9. DOI: 10.30629/0023-2149-2020-98-3-203-209. (in Russian)
6. Alieva A.M., Teplova N.V., Kislyakov V.A., Voronkova K.V., SHnahova L.M., Valiev R.K. et al. Biomarkery v kardiologii: mikroRNK i serdechnaya nedostatochnost’. Terapiya. 2022; 1: 60-70. DOI: 10.18565/therapy.2022.1.60-70. (in Russian)
7. Kuznik B.I., Chalisova N.I. Hormone adropine: its effect on age-associated diseases. Molekulyarnaya meditsina. 2021; 19 (2): 16-25. DOI: 10.29296/24999490-2021-02-03. (in Russian)
8. Bozic J., Kumric M., Ticinovic Kurir T., Males I., Borovac J.A., Martinovic D. et al. Role of Adropin in Cardiometabolic Disorders: From Pathophysiological Mechanisms to Therapeutic Target. Biomedicines. 2021; 9 (10): 1407. DOI: 10.3390/biomedicines9101407.
9. Danolic M.J., Perkovic D., Petric M., Barisic I., Gugo K., Bozic J. Adropin Serum Levels in Patients with Primary Sjögren’s Syndrome. Biomolecules. 2021; 11: 1296. DOI: 10.3390/biom11091296.
10. Kumar K.G., Trevaskis J.L., Lam D.D., Sutton G.M., Koza R.A., Chouljenko V.N. et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008; 8 (6): 468-81. DOI: 10.1016/j. cmet.2008.10.011.
11. Mushala B.A.S., Scott I. Adropin: A hepatokine modulator of vascular function and cardiac fuel metabolism. Am. J. Physiol. Heart Circ. Physiol. 2021; 320: H238-44. DOI: 10.1152/ajpheart.00449.2020.
12. Wong C.M., Wang Y., Lee J.T., Huang Z., Wu D., Xu A. et al. Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. J. Biol. Chem. 2014; 289: 25976-86. DOI: 10.1074/jbc.M114.576058.
13. Gao S., McMillan R.P., Jacas J., Zhu Q., Li X., Kumar G.K. et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes. 2014; 63: 3242-52. DOI: 10.2337/db14-0388.
14. Stein L.M., Yosten G.L., Samson W.K. Adropin acts in brain to inhibit water drinking potential interaction with the orphan G protein-coupled receptor, GPR19. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2016; 310: R476-80. DOI: 10.1152/ajpregu.00511.2015.
15. Rao A., Herr D.R. G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells. Biochim. Biophys. Acta Mol. Cell Res. 2017; 1864: 1318-27. DOI: 10.1016/j. bbamcr.2017.05.001.
16. Thapa D., Stoner M.W., Zhang M., Xie B., Manning J.R., Guimaraes D. et al. Adropin regulates pyruvate dehydrogenase in cardiac cells via a novel GPCR-MAPK-PDK4 signaling pathway. Redox Biol. 2018; 18: 25-32. DOI: 10.1016/j.redox.2018.06.003.
17. Zang H., Jiang F., Cheng X., Xu H., Hu X. Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index. Endocr. J. 2018; 65 (7): 685-91. DOI: 10.1507/endocrj. EJ18-0060.
18. Gao S., McMillan R.P., Zhu Q., Lopaschuk G.D., Hulver M.W., Butler A.A. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol. Metab. 2015; 4: 310-24. DOI: 10.1016/j.molmet.2015.01.005.

19. Thapa D., Xie B., Manning J.R., Zhang M., Stoner M.W., Huckestein B.R. et al. Adropin reduces blood glucose levels in mice by limiting hepatic glucose production. Physiol. Rep. 2019; 7: e14043. DOI: 10.14814/phy2.14043.
20. Gao S., Ghoshal S., Zhang L., Stevens J.R., McCommis K.S., Finck B.N. et al. The peptide hormone adropin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity. J. Biol. Chem. 2019; 294: 13366-77. DOI: 10.1074/jbc.RA119.008967.
21. Jasaszwili M., Wojciechowicz T., Billert M., Strowski M.Z., Nowak K.W., Skrzypski M. Effects of adropin on proliferation and differentiation of 3T3-L1 cells and rat primary preadipocytes. Mol. Cell. Endocrinol. 2019; 496: 110532. DOI: 10.1016/j.mce.2019.110532.
22. Jasaszwili M., Billert M., Strowski M.Z., Nowak K.W., Skrzypski M. Adropin as A Fat-Burning Hormone with Multiple Functions—Review of a Decade of Research. Molecules. 2020; 25: 549. DOI: 10.3390/molecules25030549.
23. Polkowska A., Pasierowska I.E., Paslawska M., Pawluczuk E., Bossowski A. Assessment of Serum Concentrations of Adropin, Afamin, and Neudesin in Children with Type 1 Diabetes. BioMed Res. Int. 2019; 2019: 6128410. DOI: 10.1155/2019/6128410.
24. Hosseini A., Shanaki M., Emamgholipour S., Nakhjavani M., Razi F., Golmohammadi T. Elevated serum levels of adropin in patients with type 2 diabetes mellitus and its association with insulin resistance. J. Biol. Today’s World. 2016; 5: 44-9. DOI: 10.15412/J. JBTW.01050301.
25. Aydin S., Kuloglu T., Aydin S., Eren M.N., Yilmaz M., Kalayci M. et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol. Cell. Biochem. 2013; 380: 73-81. DOI: 10.1007/s11010-013-1660-4.
26. Altamimi T.R., Gao S., Karwi Q.G., Fukushima A., Rawat S., Wagg C.S. et al. Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. Metabolism. 2019; 98: 37-48. DOI: 10.1016/j.metabol.2019.06.005.
27. Ticinovic Kurir T., Milicevic T., Novak A., Vilovic M., Bozic J. Adropin — potential link in cardiovascular protection for obese male type 2 diabetes mellitus patients treated with liraglutide. Acta Clin. Croat. 2020; 59 (2): 344-50. DOI: 10.20471/acc.2020.59.02.19.
28. Soltani S., Beigrezaei S., Malekahmadi M., Clark C.C.T., Abdollahi S. Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies. BMC Endocr. Disord. 2023; 23 (1): 73. DOI: 10.1186/s12902-023-01327-0.
29. Bozic J., Borovac J.A., Galic T., Kurir T.T., Supe-Domic D., Dogas Z. Adropin and Inflammation Biomarker Levels in Male Patients with Obstructive Sleep Apnea: A Link with Glucose Metabolism and Sleep Parameters. J. Clin. Sleep Med. 2018; 14: 1109-18. DOI: 10.5664/jcsm.7204.
30. Wen F., Liu Y., Wang H. Clinical Evaluation Tool for Vascular Health-Endothelial Function and Cardiovascular Disease Management. Cells. 2022; 11 (21): 3363. DOI: 10.3390/cells11213363.
31. Lovren F., Pan Y., Quan A., Singh K.K., Shukla P.C., Gupta M. et al. Adropin is a novel regulator of endothelial function. Circulation. 2010; 122: S185-92. DOI: 10.1161/CIRCULATIONAHA.109.931782.
32. Yang C., DeMars K.M., Candelario-Jalil E. Age-Dependent Decrease in Adropin is Associated with Reduced Levels of Endothelial Nitric Oxide Synthase and Increased Oxidative Stress in the Rat Brain. Aging Dis. 2018; 9 (2): 322-30. DOI: 10.14336/AD.2017.0523.
33. Yu L., Lu Z., Burchell S., Nowrangi D., Manaenko A., Li X. et al. Adropin preserves the blood-brain barrier through a Notch1/Hes1 pathway after intracerebral hemorrhage in mice. J. Neurochem. 2017; 143 (6): 750-60. DOI: 10.1111/jnc.14238.
34. Topuz M., Celik A., Aslantas T., Demir A.K., Aydin S., Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J. Investig. Med. 2013; 61: 1161-4. DOI: 10.2310/JIM.0000000000000003.
35. Oruc C.U., Akpinar Y.E., Dervisoglu E., Amikishiyev S., Salmaslıoglu A., Gurdol F. et al. Low concentrations of adropin are associated with endothelial dysfunction as assessed by flow-mediated dilatation in patients with metabolic syndrome. Clin. Chem. Lab. Med. 2017; 55: 139-44. DOI: 10.1515/cclm-2016-0329.
36. Sato K., Yamashita T., Shirai R., Shibata K., Okano T., Yamaguchi M. et al. Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation. Int. J. Mol. Sci. 2018; 19: 1293. DOI: 10.3390/ijms19051293.
37. Yu H.Y., Zhao P., Wu M.C., Liu J., Yin W. Serum adropin levels are decreased in patients with acute myocardial infarction. Regul. Pept. 2014; 190-191: 46-9. DOI: 10.1016/j.regpep.2014.04. 001.
38. Celik A., Balin M., Kobat M.A., Erdem K., Baydas A., Bulut M. et al. Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc. Ther. 2013; 31: 174-8. DOI: 10.1111/1755-5922.12025.
39. Gu X., Li H., Zhu X., Gu H., Chen J., Wang L. et al. Inverse correlation between plasma adropin and ET-1 levels in essential hypertension: A cross-sectional study. Medicine. 2015; 94: e1712. DOI: 10.1097/MD.0000000000001712
40. Bolayir H.A., Kivrak T., Gunes H., Bolayir A., Karaca I. Adropin and circadian variation of blood pressure. Kardiol. Pol. 2018; 76: 776-82. DOI: 10.5603/KP.2018.0006.
41. Boric-Skaro D., Mizdrak M., Luketin M., Martinovic D., Tokic D., Vilovic M. et al. Serum Adropin Levels in Patients on Hemodialysis. Life (Basel). 2021; 11 (4): 337. DOI: 10.3390/life11040337.
42. Chen M., Ouyang F., Zhou S. Adropin as a novel energy factor likely has the ability to regulate blood pressure. Med. Hypotheses. 2015; 85 (2): 234. DOI: 10.1016/j.mehy.2015.04.010.
43. Fujie S., Hasegawa N., Sato K., Fujita S., Sanada K., Hamaoka T. et al. Aerobic exercise training-induced changes in serum adropin level are associated with reduced arterial stiffness in middle-aged and older adults. Am. J. Physiol. Heart Circ. Physiol. 2015; 309: H1642-7. DOI: 10.1152/ajpheart.00338.2015.
44. Zheng J., Liu M., Chen L., Yin F., Zhu X., Gou J. et al. Association between serum adropin level and coronary artery disease: a systematic review and meta-analysis. Cardiovasc. Diagn. Ther. 2019; 9 (1): 1-7. DOI: 10.21037/cdt.2018.07.09.
45. Wang H., Wang X., Cao Y., Han W., Guo Y., Yang G. et al. Association of polymorphisms of preptin, irisin and adropin genes with susceptibility to coronary artery disease and hypertension. Medicine (Baltimore). 2020; 99 (10): e19365. DOI: 10.1097/MD.0000000000019365.
46. Wei N., Zhang R., Zhu Z., Li R., Yu Q., Wang Q. et al. Adropin and Irisin Deficiencies Are Associated with Presence of Diagonal Earlobe Crease in CAD Patients. Front. Cardiovasc. Med. 2021; 8: 719763. DOI: 10.3389/fcvm.2021.719763.
47. Akkaya H., Gunturk E.E., Akkaya F., Karabıyik U., Gunturk I., Yilmaz S. Assessment of the Relationship Between the Adropin Levels and the Coronary Collateral Circulation in Patients wıth Chronic Coronary Syndrome. Arq. Bras. Cardiol. 2022; 119 (3): 402-10. DOI: 10.36660/abc.20210573.
48. Ozkan B., Orscelik O., Yildirim Yaroglu H., Balci S., Ozcan M.K., Celik A. et al. Association between serum adropin levels and isolated coronary artery ectasia in patients with stable angina pectoris. Anatol. J. Cardiol. 2019; 22 (5): 250-5. DOI: 10.14744/AnatolJCardiol.2019.90349.
49. Uysal B.A., Kuyumcu M.S. Serum irisin and adropin levels may be predictors for coronary artery ectasia. Clin. Exp. Hypertens. 2022; 44 (3): 223-7. DOI: 10.1080/10641963.2021.2018601.
50. Wang B., Xue Y., Shang F., Ni S., Liu X., Fan B. et al. Association of serum adropin with the presence of atrial fibrillation and atrial remodeling. J. Clin. Lab. Anal. 2019; 33 (2): e22672. DOI: 10.1002/jcla.22672.
51. Berezina T.A., Obradovic Z., Boxhammer E., Berezin A.A., Lichtenauer M., Berezin A.E. Adropin Predicts Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure. J. Clin. Med. 2023; 12 (6): 2231. DOI: 10.3390/jcm12062231.
52. Celikhisar H., Ilkhan G.D. Alterations in serum adropin, adiponectin, and proinflammatory Cytokine Levels in OSAS. Can. Respir. J. 2020; 2020: 2571283. DOI: 10.1155/2020/2571283.
53. Fan Z., Zhang Y., Zou F., Xu T., Pan P., Hu C. et al. Serum adropin level is associated with endothelial dysfunction in patients with obstructive sleep apnea and hypopnea syndrome. Sleep Breath. 2021; 25 (1): 117-23. DOI: 10.1007/s11325-020-02072-7.

Ключевые слова